The Beetham Eye Institute (BEI) at Joslin Diabetes Center has been recognized as one of the top institutions worldwide for research and treatment of diabetic retinopathy by Expertscape.
– The Asian American Diabetes Initiative (AADI) at Joslin Diabetes Center has received a $70,089 grant from Tufts Health Plan Foundation to fund Healthy Living for All Seasons, which offers elderly Asians with, or at risk for, diabetes the opportunity to take part in educational workshops and seminars focusing on exercise, improved diet, and the prevention of diabetes complications.
A new study conducted by Robert A. Gabbay, M.D., Ph.D., FACP, Senior Vice-President and Chief Medical Officer at Joslin Diabetes Center and Harvard Medical School, and colleagues identified three core factors and thirteen strategies that increase the probability of getting buy-in from the practice teams within a medical practice to becoming a fully-functioning patient-centered medical home (PCMH).
A new study by Joslin Diabetes Center researchers that compares the metabolic fingerprints of patients who develop ESRD versus those who don’t has furnished new clues to the disease.
Joslin Diabetes Center, an affiliate of Harvard Medical School, has launched a pilot program in conjunction with Truman Medical Centers, the primary teaching hospital for the University of Missouri-Kansas City Schools of Medicine to test the capabilities of a novel and innovative care analytics tool called the Joslin Clinical Analytical Tool (JCAT™).
Researchers at Joslin Diabetes Center have discovered that a hormone long associated with weight loss and improved glucose metabolism is linked to activation of calorie-burning brown fat.
Today, the Centers for Disease Control (CDC) released the National Health and Nutritional Examination Survey (NHANES) with additional data briefs on hypertension, cholesterol and obesity among adults in the U.S. by age, gender, race and ethnicity.
Joslin researchers have gained new insights into how obesity and type 2 diabetes can create a stress response in the brain, especially in the hypothalamus (the brain region that regulates appetite and energy production), that may contribute to altering metabolism throughout the body.
The National Institutes of Health awarded Joslin Diabetes Center $24.3 million to fund a clinical trial to study a potential treatment for kidney disease in people with type 1 diabetes.
Joslin Diabetes Center today announced that Peng Yi, Ph.D., has been appointed an Assistant Investigator in the Islet Cell and Regenerative Biology Section of Joslin’s Research Division.
The First Helmholtz Diabetes Lecture Award will be presented to C. Ronald Kahn, M.D. at the upcoming Helmholtz-Nature Medicine Diabetes Conference. Dr Kahn is a resident of Newton, MA, and Chief Academic Officer of Joslin Diabetes Center. He will receive this honor at the conference on September 22 - 24, 2013 in Munich, Germany.
Good Measures and Joslin Diabetes Center announced today that they have reached an agreement, aimed at incorporating Joslin’s nutritional guidelines, meal plans, exercise recommendations and other relevant resources into Good Measures’ product and service offerings.
Joslin scientists, in collaboration with researchers from the Harvard School of Public Health and Italian research institutes, have identified a previously unknown genetic variant associated with an increased risk of coronary heart disease (CHD) in type 2 diabetic patients. This discovery has the potential to lead to the development of new treatments for CHD in diabetic patients.
The American Association for Clinical Chemistry (AACC) will present C. Ronald Kahn, M.D., of Newton, MA, with the Wallace H. Coulter Lectureship Award at its 2013 Annual Meeting and Clinical Exposition in Houston, Texas on July 28. The Wallace H. Coulter Lectureship Award goes to an individual who has demonstrated a lifetime commitment to, and made important contributions that have had a significant impact on education, practice and/or research in laboratory medicine or patient care. Dr. Kahn was selected to receive this award based on his 40 year commitment to the field of diabetes and obesity research, in particular his significant work in insulin signal transduction and the mechanisms of altered insulin signaling in disease.
Researchers at Joslin Diabetes Center have discovered that when excessive PKC beta is found in the endothelium, the thin layer of cells that line blood vessels, atherosclerosis is exacerbated. Their findings could lead to treatments to reduce the risk of CVD in people with type 1 and type 2 diabetes.
Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.
Scientists at Joslin Diabetes Center in Boston report significant findings about the location, genetic expression and function of human brown adipose tissue (BAT) and the generation of new BAT cells. These may contribute to further study of BAT’s role in human metabolism and developing treatments that use BAT to promote weight loss
“These findings highlight the limitations of basing mealtime insulin dosing for type 1 diabetes solely on carbohydrate intake,” says Dr. Wolpert. “We need to consider fat as well as carbohydrates in insulin dosing calculations as well as in nutritional recommendations.”
Joslin scientists have discovered a mechanism that regulates the production of brown fat, a type of fat which plays an important role in heat production and energy metabolism. The findings may lead to new therapies that increase BAT formation to treat obesity.
Scientists at Joslin Diabetes Center in Boston report the first generation of human induced pluripotent stem cells from patients with an uncommon form of diabetes, maturity onset diabetes of the young (MODY). These cells offer a powerful resource for studying the role of genetic factors in the development of MODY and testing potential treatments.
Joslin Diabetes Center scientists have identified a cell cycle transcriptional co-regulator – TRIP-Br2 – that plays a major role in energy metabolism and fat storage. This finding has the potential to lead to new treatments for obesity.
Joslin Diabetes Center scientists have demonstrated that brown adipose tissue (BAT) has beneficial effects on glucose tolerance, body weight and metabolism.
Researchers led by Stephan Kissler, Ph.D., have demonstrated how a genetic variant associated with type 1 diabetes and other autoimmune diseases influences susceptibility to autoimmunity.
Joslin Diabetes Center, Boston, Massachusetts, has been awarded a $9.5 million, multi-year Diabetes Research Center (DRC) grant from the National Institutes of Diabetes, Digestive and Kidney Disorders (NIDDK) of the National Institute of Health (NIH).
Scientists at Joslin Diabetes Center have identified a new factor — microRNA processing in fat tissue — which plays a major role in aging and stress resistance. This finding may lead to the development of treatments that increase stress resistance and longevity and improve metabolism.
Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes.
Scientists have been puzzled by the fact that after people with type 1 diabetes have a heart attack, their long-term chance of suffering even more heart damage skyrockets. Dr. Myra Lipes and team at Joslin Diabetes Center have identified the misstep that sparks this runaway chronic damage and a promising way to block it.
A study by a team of clinicians and researchers at Joslin Diabetes Center in Boston has shown for the first time that patients with diabetes who enrolled in a short-term intensive weight management program were able to lose weight and keep it off on their own for four years. The findings suggest an alternative course to bariatric surgery in the fight against type 2 diabetes.
Researchers at Joslin Diabetes Center have shown that while a type of “good” fat found in the body can be activated by cold temperatures, it is not able to be activated by the drug ephedrine.
Scientists at Joslin Diabetes Center have identified a key mechanism of action for the TOR (target of rapamycin) protein kinase, a critical regulator of cell growth which plays a major role in illness and aging. This finding not only illuminates the physiology of aging but could lead to new treatments to increase lifespan and control age-related conditions, such as cancer, type 2 diabetes, and neurodegeneration.
Joslin Diabetes Center, the world’s largest diabetes research and care institution and an affiliate of Harvard Medical School, today announced the appointment of Rajni Aneja, M.D., M.B.A., C.P.E., as Executive Vice President. Dr. Aneja comes to Joslin from WebMD, where she was Chief Medical officer for WebMD health services.
Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes. The findings have immediate diagnostic implications and can be used for the development of new therapies to prevent or postpone the progression of renal disease in diabetes.
Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body’s ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.
Joslin Diabetes Center has received a $3.9 million DP3 grant from the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health to identify protective factors that enable many a unique cohort of Joslin patients to remain free of commonly occurring diabetes complications in spite of living with diabetes for more than 50 years.
In a paper published today in Diabetologia, a team at Joslin Diabetes Center, headed by Mary R. Loeken, PhD, has identified the enzyme AMP kinase (AMPK) as key to the molecular mechanism that significantly increases the risk of neural tube defects such as spina bifida and some heart defects among babies born to women with diabetes.
Researchers at the Joslin Diabetes Center have identified for the first time two molecular pathways that are critical to activating a type of “good” fat found in the body, called brown fat, which actually burns energy rather than storing it, which the more common white fat does. This discovery could play an important role in the fight against obesity and diabetes.
Researchers at the Joslin Diabetes Center have shown that an enzyme found in the mitochondria of cells is decreased in the skeletal muscle of those with type 2 diabetes, a finding that could lead to the development of drugs to boost the activity of this enzyme in an effort to fight the disease.
Researchers at Joslin Diabetes Center and Children’s Hospital Boston have shown that a type of “good” fat known as brown fat occurs in varying amounts in children – increasing until puberty and then declining -- and is most active in leaner children.
Joslin scientists have uncovered a new way in which obesity wreaks its havoc, by altering the production of proteins that affect how other proteins are spliced together. Their finding may point toward novel targets for diabetes drugs.
A study led by researchers at the Joslin Diabetes Center suggests that adding the amino acid leucine to their diets may help those with pre-diabetes or metabolic syndrome.
A study by Joslin Diabetes Center researchers has found that some people who have survived diabetes for many decades show remarkably few complications—a discovery that points toward the presence of protective factors that guard against the disease's effects.
The International Diabetes Federation now recommends that surgery be considered as a treatment for obese patients with type 2 diabetes. Dr. Allison Goldfine, head of clinical research at Joslin Diabetes Center, is available for comment.
People with type 1 diabetes, whose insulin-producing cells have been destroyed by the body’s own immune system, are particularly vulnerable to a form of inflammatory heart disease caused by a different autoimmune reaction. Scientists at Joslin Diabetes Center now have revealed the exact target of this other onslaught.